ARAVIVE (ARAV)
(Delayed Data from NSDQ)
$0.04 USD
0.00 (0.00%)
Updated Jan 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
ARAVIVE, INC [ARAV]
Reports for Purchase
Showing records 21 - 40 ( 104 total )
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2Q22:Two Clinical Updates in the Second Half of 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Batiraxcept?s Best in Class Potential For Targeted Therapy in ccRCC Highlighted at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
We are initiating with a Buy rating and $15 PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
KOL Event Highlights Batiraxcept Differentiated Profile Across Indications; While Market Struggles, Aravive Delivers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2021 Results; Busy Data Year as PROC Phase 3 Marches to Full Enrollment in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
First Look at Batiraxcept in ccRCC Impresses; Data Point to Broader Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
3Q21 Results; SITC Update Should Highlight the Opportunity in ccRCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Broadens its Reach; First Patient Dosed in Phase 1b/2 Pancreatic Cancer Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2Q21 Results; AVB-500 Approaching Key Steps Across Rich Oncology Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Global Clinical Development Continues With Second Milestone Payment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Exhibits Promising Safety and PK Profile in ccRCC; Phase 2 Up Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
1Q21 Results; AVB-500 Profile Continues to Broaden; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Officially Goes Pivotal; Simplified SAP; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2020 Results; AVB-500 On Track to Deliver Key Milestones in PROC and ccRCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J